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Abstract  24 
We showed that Parathyroid Hormone-related Peptide (PTHrP) induces 25 
proliferation, migration, survival and chemoresistance via MAPKs and PI3K/AKT 26 
pathways in colorectal cancer (CRC) cells. The objective of this study was to 27 
investigate if PTHrP is also involved in tumor angiogenesis. PTHrP increased 28 
VEGF expression and the number of structures with characteristics of neoformed 29 
vessels in xenografts tumor. Also, PTHrP increased mRNA levels of VEGF, HIF-1α 30 
and MMP-9 via ERK1/2 and PI3K/Akt pathways in Caco-2 and HCT116 cells. 31 
Tumor conditioned media (TCMs) from both cell lines treated with PTHrP increases 32 
the number of cells, the migration and the tube formation in the endothelial HMEC-33 
1 cells, whereas the neutralizing antibody against VEGF diminished this response. 34 
In contrast, PTHrP by direct treatment only increased ERK1/2 phosphorylation and 35 
the HMEC-1 cells number. These results provide the first evidence related to the 36 
mode of action of PTHrP that leads to its proangiogenic effects in the CRC.  37 
Highlights:  38 
PTHrP has indirect proangiogenic effects in the CRC via VEGF. 39 
PTHrP mediates the interaction of colon tumor cells with the endothelial cells.  40 
PTHrP does not stimulate directly migration neither tube formation of endothelial 41 
cells. 42 
Keywords: PTHrP; colon cancer; tumor angiogenesis; VEGF 43 
Abbreviations: PTHrP: Parathyroid Hormone-related Peptide; CRC: colorectal 44 
cancer; TCMs: tumor conditioned media. 45 
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1. Introduction 47 
 48 
Parathyroid hormone-related protein (PTHrP) has a high homology with 49 
parathyroid hormone (PTH) in its N‑terminal amino acid sequence, so it activates 50 
the PTH/PTHrP receptor (PTHR1) mimicking the action of this hormone (Nikitovic 51 
et al., 2016). Interestingly, this peptide has wide spread distribution in fetal and 52 
adult tissues with physiologic or pathologic functions through endocrine, paracrine, 53 
autocrine or intracrine signaling (McCauley and Martin, 2012). 54 
With respect to its role in pathologies, PTHrP was initially involved with cancers, 55 
mainly as inductor of hypercalcemia but is also associated with osteoporosis and 56 
osteoarthritis, so this hormone can be keeping in mind to be used in therapy 57 
(Wysolmerski , 2012). Furthermore, recent research indicates that the peptide has 58 
also a critical role in the progression of skeletal metastasis (Zheng et al., 2018) and 59 
other different critical features that massively contributes to malignant behavior of 60 
different cancers such as colorectal cancer (CRC) (McCauley and Martin, 2012; 61 
Hong et al., 2016), CRC is one of the main causes of cancer death in the world 62 
(Siegel et al., 2017) where angiogenesis has a critical role (Battaglin, 2018). 63 
One attractive target in cancer therapy is the process of angiogenesis, which is the 64 
formation of new blood vessels from a pre-existing network of capillaries, because 65 
it allows the supply of oxygen and nutrients to the tumor cells and it contributes to 66 
the metastasis. Thus, it is important for the growth and metastasis of various types 67 
of cancers, such as CRC. The wide process of angiogenesis involves the 68 
activation, proliferation and migration of vascular endothelial cells and a fine 69 
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equilibrium between molecules with pro-angiogenic or anti-angiogenic effects, 70 
which leads to the subsequent reconstruction and formation of vascular structures 71 
(Loizzi et al., 2017; Kong et al., 2017). The loss of this balance affects the 72 
progression of the CRC (Battaglin et al., 2018). A pro-angiogenic factor secreted 73 
by endothelial and tumor cells is the vascular endothelial cell growth factor (VEGF), 74 
which interacts with three subtypes of the vascular endothelial growth factor 75 
receptor (VEGFR), numbered 1, 2 and 3. VEGFR2 mediates a wide range of 76 
VEGF physiological responses in endothelial cells by activating downstream 77 
signaling pathways, such as ERK1/2, c-Src, Akt, endothelial nitric oxide and p38 78 
MAPK (Koch et al., 2011; Greenberg et al., 2008). Despite the use of therapeutic 79 
agents directed to the inhibition of angiogenesis in the treatment of metastatic CRC 80 
(Battaglin et al., 2018), it has been observed the resistance of many patients 81 
leading to the treatment failure and the progression of the disease. Therefore, the 82 
knowledge of the mechanisms involved in angiogenesis is of great importance to 83 
provide new therapeutic alternatives. 84 
In previous studies, we observed that PTHrP activates ERK1/2 and p38 MAPK, as 85 
well as the serine-threonine kinase AKT in the two cell lines from human colon 86 
tumors, Caco-2 and HCT116 cells. In these cells, the hormone increases cell 87 
proliferation and promotes survival under apoptotic conditions via MAPKs and 88 
PI3K/AKT signaling pathways (Lezcano et al., 2013; Martín et al 2014; Calvo et al., 89 
2014).  90 
In both cell lines the hormone also activates p90 ribosomal S6 kinase (RSK) and 91 
increases cell migration via ERK1/2-RSK but independently of p38 MAPK signaling 92 
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pathway (Calvo et al., 2017). Recently, we found that PTHrP induces 93 
chemoresistance in Caco-2 and HCT116 cells through mitogenic signaling 94 
pathways such ERK and Akt (Martin et al., 2018). Also, the administration of 95 
PTHrP in HCT 116 xenografts of nude mice, increased the expression of RSK and 96 
others markers related to tumorigenic events (Calvo et al., 2017; Martín et al., 97 
2018). 98 
PTHrP is involved in different types of tumors, however, its precise and direct role 99 
in angiogenesis is controversial and it is not clear (Bakre et al., 2002; Akino et al., 100 
2000). Furthermore, it is unknown if this hormone is involved in tumor-associated 101 
angiogenesis in the CRC. It is well established that the signaling pathways 102 
regulated by PTHrP in the cell lines derived from CRC and in xenografts of nude 103 
mice may participate in angiogenesis (Xu et al., 2015; Hammoud et al., 2016; Dong 104 
et al., 2017). Therefore, the objective of the present study was to investigate, both 105 
in vitro and in vivo models, whether PTHrP has a role in Tumor-Associated 106 
Angiogenesis and if so, the molecular mechanisms that are involved in this 107 
process. In this work, we hypothesized that PTHrP is an important factor that 108 
stimulates the interaction between the microenvironment endothelial cells and 109 
colon cancer cells mainly through the secretion of pro-angiogenic factors by colon 110 
cancer cells treated with the hormone. 111 
We suppose that tumor angiogenesis is subsequent to this interaction and 112 
therefore it is also facilitated by the hormone.  113 
 114 
2. Materials and methods 115 
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2.1. Materials 116 
Human PTHrP (1-34), high glucose Dubelcco’s modified Eagle’s medium (DMEM) 117 
and Trypan blue dye were obtained from Sigma-Aldrich Chemical Co. (St. Louis, 118 
Missouri, USA). Fetal bovine serum (FBS) was from Natocord (Córdoba, 119 
Argentina). Anti-phopho ERK1/2 and antiCD-31 were from Cell Signaling 120 
Technology (Beverly, Massachusetts, USA). Anti-VEGF, anti-GAPDH, goat anti-121 
rabbit peroxidase conjugated secondary antibody and goat anti-mouse peroxidase 122 
conjugated secondary antibody were from Santa Cruz Biotechnology (Santa Cruz, 123 
California, USA). Mouse monoclonal antibody against PTH receptor (opossum 124 
kidney) was from BAbCO (Richmond, California). PD 98059 and LY 294002 were 125 
from Calbiochem (San Diego, California, USA). GSK690693 was from Santa Cruz 126 
Biotechnology (Santa Cruz, California, USA). Crystal violet was from MERCK 127 
(Buenos Aires, Argentina). Protein size markers were from Amersham Biosciences 128 
(Piscataway, New Jersey, USA), PVDF (Immobilonpolyvinylidene difluoride) 129 
membranes and ECL chemiluminescence detection kit were from Amersham (Little 130 
Chalfont, Buckinghamshire, England). Geltrex was from Invitrogen (Carlsbad, 131 
California, USA). Transwell filters of polyethylene terephthalate (PET), 8 µm pores, 132 
24-well format, were from JETBIOFIL. All other reagents used were of analytical 133 
grade. 134 
 135 
2.2. Xenograft in nude mice  136 
We injected subcutaneously 1 × 106 human colorectal carcinoma HCT116 cells 137 
into the left dorsal flanks of 6-week-old N:NIH(S)_nu mice. The number of mice in 138 
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each group, the dose of PTHrP(1-34) (for treatment group) and its vehicle PBS (for 139 
control group) and the administration scheme were chosen according our previous 140 
studies (Calvo et al., 2017; Martín el al., 2018). The animals were sacrificed and 141 
tumors were removed after 20 days of PTHrP treatment (Wang et al., 2002). All 142 
experiments with animals were approved by a local animal committee for ethics. 143 
One piece of each tumor was immediately frozen in liquid nitrogen and maintained 144 
at -80 ºC until the corresponding analysis by real-time quantitative T-PCR assay 145 
and another piece was fixed with 4% neutral buffered formaldehyde solution for 146 
immunohistochemistry assay. Total RNA from three piece of each tumor was 147 
isolated; following with the RNA quantification, the synthesis of the cDNA and the 148 
PCR reaction carried out in a real-time PCR system. 149 
 150 
2.3. Colon cancer cells culture and treatment 151 
 152 
The human colon cell lines Caco-2 and HCT 116 (from the American Type Culture 153 
Collection, Manassas, Virginia) were cultured at 37 °C in DMEM that contains 10% 154 
FBS, 1% non-essential acids, 100 UI/mL penicillin, 100 mg/mL streptomycin and 155 
50 mg/mL gentamycin in a humid atmosphere of 5% CO2 in air. We used cells with 156 
80% confluence. Cells were FBS-deprived 24 h for Caco-2 cells and 2 h for HCT 157 
116 cells and then treated with PTHrP (1-34) at different times, using a dose of 10-8 158 
M which was chosen in previous studies (Lezcano et al., 2013; Martín et al., 2014; 159 
Calvo et al., 2014). In some experiments, cells were pretreated for 30 min with PD 160 
98059 (an inhibitor of MEK, which is the upstream kinase of ERK1/2), LY 294002 161 
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(an inhibitor of PI3kinase), GSK690693 (an inhibitor of Akt kinase) or with an 162 
equivalent volume of the vehicle of the inhibitors (DMSO) as control. The inhibitors 163 
doses employed were obtained according to previous studies (Lezcano et al., 164 
2013; Martín et al., 2014; Calvo et al., 2014; Mahfouz et al., 2017). 165 
 166 
2.4. Tumor conditioned media (TCMs) preparation 167 
We obtained colon tumor conditioned media (TCMs) from cultured media of Caco-168 
2 or HCT 116 cells after 24 h incubation with or without 10−8 M PTHrP (1-34), 169 
always following the same cells/volume ratio. TCMs were collected, centrifuged for 170 
10 min at 10,000 rpm to eliminate cell debris and the supernatants were stored at 171 
−80 °C until assayed. The protein content was measured to normalize the results. 172 
 173 
2.5. Endothelial Cell culture, treatment and co-culture 174 
HMEC-1 is an immortalized cell line which retains the morphology, phenotype and 175 
function of normal human microvascular endothelial cells. HMEC-1 cells (from the 176 
American Type Culture Collection, Manassas, Virginia) were cultured at 37 °C in 177 
high glucose DMEM supplemented with 10% FBS, 1% non-essential acids, 100 178 
UI/mL penicillin, 100 mg/mL streptomycin and 50 mg/mL gentamycin in a humid 179 
atmosphere of 5% CO2 in air. We used this experimental model because the 180 
microvascular endothelial cell line is mainly involved in clinically relevant 181 
angiogenesis capillary sprouting in vivo (Folkman, 2006), and the effect of 182 
PTHrP(1-34) on these cells has not yet been studied.  183 
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The treatments were according to the assay. For measuring of endothelial cells 184 
number, HMEC-1 cells were treated with the corresponding TCMs or with 185 
PTHrP(1-34). For endothelial cell migration assay, in some experiments HMEC-1 186 
cells were cultured with DMEM without serum and the corresponding TCMs or the 187 
hormone were used as chemoattractants and in others, endothelial cells were 188 
directly exposed with PTHrP(1-34) and DMEM with serum was used as 189 
chemoattractant. In co-culture experiments, endothelial cells and colon cancer cells 190 
were seeded using transwell filters. Finally, in tube formation assay, HMEC-1 cells 191 
were cultured with the corresponding TCMs or with the hormone which was directly 192 
applied to the cells seeded on geltrex matrix. 193 
 194 
2.6. RNA Isolation and cDNA Synthesis 195 
First, we isolate the total RNA from all pieces of the tumor employing the 196 
EasyPure® RNA Kit (TRANS, Beijing, China) and from all samples of colon cancer 197 
cell lines employing the High Pure RNA Isolation Kit (Roche Diagnostics, 198 
Mannheim, Germany) taking into account the manufacturer’s instructions in both 199 
isolations. Then, we synthesize the cDNA using High Capacity cDNA Reverse 200 
Transcription Kits following the manufacturer's instructions (Applied Biosystems, 201 
USA) and we store it at −20 °C for real-time quantitative RT-PCR (qRT-PCR). 202 
 203 
2.7. Real-Time Quantitative RT-PCR 204 
The PCR reaction was performed in a real-time PCR system (Applied Biosystems, 205 
model 7500), using SYBR green master mix (No. 4309159, Applied Biosystems) 206 
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for PCR reactions according previous works (Calvo et al., 2014). The primers used 207 
were the following: 5´-CACCTCTGGACTTGCCTTTC-3´ (forward) and 5´- 208 
GGCTGCATCTCGAGACTTTT-3´(reverse) for HIF-1α; 5´- 209 
TGCAGATTATGCGGATCAAACC-3´ (forward) and 5´- 210 
TGCATTCACATTTGTTGTGCTGTAG-3´(reverse) for VEGF; 5´- 211 
CCTTCACTTTCCTGGGTAAG-3´ (forward) and 5´- 212 
CCATTCACGTCGTCCTTATG-3´(reverse) for MMP-9; 5´- 213 
ACCACAGTCCATGCCATCA-3´ (forward) and 5´- TCCACCAC CTGTTGCTGTA-214 
3´(reverse) for GAPDH. We obtained mRNA levels according to the 2−∆CT equation 215 
and with respect to the corresponding control.  216 
 217 
2.8. Immunohistochemistry 218 
First, we deparaffinised the paraffin embedded sections and re-hydrated them. 219 
Then, we performed the antigen retrieval using heat and a sodium citrate buffer (10 220 
mM, pH 6) for 15 minutes. The sections were washed with PBS, blocked in 30% 221 
H2O2 and incubated with the primary antibody (anti-VEGF or anti-CD31) overnight 222 
at 4ºC. We employed ABCAM Detection IHC Kit (ABCAM, Cambridge, MA, USA) 223 
according to the manufacturer's instructions. Finally, the reaction was stopped with 224 
distilled water according to microscopic observation and, counterstained with 225 
hematoxylin, dehydrated, and coverslipped. The slides were visualized using a 226 
light microscope. 227 
 228 
2.9. Measuring of the number of cells 229 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
2.9.1. Crystal violet staining. A 96-well plate seeded with HMEC-1 cells (20,000 230 
cells/ well) and cultured with the corresponding TCMs or the hormone at 37 °C for 231 
24 h. Cells were washed with PBS, fixed with methanol for 10 min at -20 °C and 232 
stained with 0.1% crystal violet for 30 min at room temperature. Then, we 233 
solubilized the dye that stained the cells with10% acetic acid and measured the 234 
solution absorbance, which is proportional to the number of cells, at 595nm. Each 235 
experiment was carried out with independently obtained TCM. 236 
2.9.2. Trypan blue dye exclusion test. Endothelial cells were washed with PBS, 237 
trypsinized to lift them from the plates and stained with 0.4% of Trypan Blue. We 238 
counted the number of viable cells that excluded the stain in a microscope using a 239 
Neubauer chamber. Each experiment was carried out with independently obtained 240 
TCM. 241 
2.9.3. Resazurin Cell Viability assay. Cell viability was evaluated by Resazurin 242 
Cell Viability Kit (Cell Signaling Technology, Beverly, Massachusetts, USA). 243 
Endothelial cells were plated for triplicate in 96- well plates. After each treatment, 244 
10 µl of the reagent was added on each well followed by 1 hour of incubation at 37 245 
°C. Viable cells retain the ability to reduce resazurin, which is blue and non-246 
fluorescent, into resorufin, which is red and brightly fluorescent. After the 247 
incubation step, the relative fluorescent units were measured. 248 
 249 
2.10. Endothelial cell migration assay 250 
We performed migration assays employing cell culture inserts (8 µm pore size). A 251 
total of 20,000 HMEC-1 cells were seeded in medium without FBS in the upper 252 
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chamber (on the top of transwell filters). Then, in some experiments, TCMs 253 
prepared as previously described or PTHrP (10-8 M) in FBS free medium was 254 
added to the bottom chambers so that the HMEC-1 cells on the top of transwell 255 
filters migrate towards the lower chamber and to evaluate the indirect or direct 256 
PTHrP effect, respectively. In others studies, to further analyze the direct PTHrP 257 
effect, the medium in filter inserts was replaced by FBS free medium with or 258 
without PTHrP (10−8 M) and medium containing 5% FBS was added in the lower 259 
chamber. For co-culture assays, Caco-2 or HCT 116 cells (15,000 cells) were 260 
previously plated into the lower chamber, grown for 48 h, serum starved for 261 
another 24 hours followed by the treatment with or without the hormone to induce 262 
secretion of angiogenic factors. Next, the inserts with HMEC-1 cells were placed in 263 
the wells with colon cancer cells. After 16 hours, the endothelial cells were washed 264 
with PBS and fixed using methanol for 10 minutes at -20 °C. This time was 265 
selected according to results of pilot experiments using as a negative control FBS 266 
free medium and as a positive control medium with 5% FBS. We removed with a 267 
cotton swab the cells on the top side of the transwell filters and then stained the 268 
cells on the botton side (migrated cells) with 0.1% crystal violet for 30 min at room 269 
temperature. In some experiments, TCMs were pre-incubated for 2 h at 37 °C prior 270 
to their use in the migration assay with a specific neutralizing antibody directed 271 
against human VEGF (0.1 µg/ml; Santa Cruz) or with an appropriate isotype-272 
matched control rabbit IgG. The antibody concentration was chosen according to 273 
literature data (Shtivelband et al., 2003). Finally, the cells that have migrated were 274 
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counted using a microscope (2 replicates/ condition, n=3 experiments). Each 275 
experiment was carried out with independently obtained TCM. 276 
 277 
2.11. Tube formation assay using geltrex matrix 278 
We employed the tube formation assay using geltrex matrix according to previous 279 
studies (Chim et al., 2011) and to evaluate the ability of endothelial cells to form an 280 
organized tubular network. Growth factor-reduced geltrex basement membrane 281 
matrix was thawed at 4 °C, added to 96well-plates (50 µL/well), and left at 37 °C 282 
for 1 h to allow gelification. Then, 20,000 HMEC-1 cells/well were seeded on 283 
geltrex and incubated with the corresponding TCMs or serum-free medium with or 284 
without PTHrP at 37 °C. After 24 h cells were examined and photographed under 285 
an inverted light microscope at 100× magnification (NIKON Eclipse Ti-S). Tube 286 
formation was quantified by measuring the number of nodes, junctions and 287 
branching points and the total branching length using ImageJ (NIH) program with 288 
the tool to analyze angiogenesis as described Carpentier (Carpentier, 2012).  289 
In some experiments, TCMs were pre-incubated for 2 h at 37 °C and then used in 290 
the geltrex assay with a specific neutralizing antibody directed against human 291 
VEGF (0.1 µg/ml; Santa Cruz) or with an appropriate isotype-matched control 292 
rabbit IgG. (2 replicates/ condition, n=3 experiments). Each experiment was carried 293 
out with independently obtained TCM. 294 
 295 
2.12. Western blot analysis  296 
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We washed the cells with PBS plus 25 mM NaF and 1 mM Na3VO4, and lysed 297 
them in buffer containing 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 3 mM KCl, 1 298 
mM EDTA,1% Tween-20, 1% Nonidet P-40, 20 µg/mL aprotinin, 20 µg/mL 299 
leupeptin,1 mM phenylmethylsulfonyl fluoride (PMSF), 25 mM NaF, and 1 mM 300 
Na3VO4. The lysates obtained were vortexed for 45 s, and centrifuged at 14 000g 301 
and 4 °C for 15 min to collect the supernatant were we performed the quantification 302 
of the proteins by the Bradford method (Bradford, 1976). Then, we performed 303 
western blot analysis according to the protocol described in our previous studies 304 
(Calvo et al., 2014; Calvo et a., 2017).   305 
 306 
2.13. Statistical analysis 307 
Statistical analysis of the data was performed using the Student's test (Snedecor 308 
and Cochran, 1989), and probability values below 0.050 (p <0.050) were 309 
considered significant. The data are expressed as the means ± SD of at least three 310 
independent experiments. 311 
 312 
3. Results 313 
3.1. PTHrP increases VEGF expression and the number of structures with 314 
characteristics of neoformed vessels in xenografts tumor 315 
Several of the signaling pathways that may participate in the regulation of pro-316 
angiogenic factors (Xu et al., 2015; Hammoud et al., 2016; Dong et al., 2017) are 317 
modulated by PTHrP in cells derived from CRC (Lezcano et al., 2013; Martín et al., 318 
2014; Calvo et al., 2014; Calvo et al., 2017; Martín et al., 2018). So, to evaluate the 319 
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possible role of the hormone in tumor-associated angiogenesis, we initially 320 
investigated the effect of PTHrP in the expression of the angiogenic factor VEGF in 321 
colorectal tumor tissues. RT-qPCR analysis of nude mice xenografts of HCT116 322 
cells exhibited increased levels of mRNA VEGF in tumors treated with PTHrP 323 
respect to the levels observed in control tumor (Figure 1A). Furthermore, we also 324 
observed increased protein levels of VEGF by immunohistochemistry analysis of 325 
these xenografts tumor (Figure 1B). According to the results showed by others 326 
authors (Domigan et al., 2015; Bhattacharya et al., 2016), the localization of VEGF 327 
was observed near the nuclear membrane and cytoplasmic, suggesting also the 328 
possible involvement of this factor in an intracrine signaling.  329 
In view of these results, we then evaluated the expression of CD31 by 330 
immunohistochemistry in HCT116 xenograft tumors treated or not with PTHrP 331 
because this marker is expressed in vascular endothelial cells and it is widely used 332 
to highlight intra-tumoral vessels and the degree of neoangiogenesis (Avdalyan et 333 
al., 2012). This protein shows the vascular status and it marks both neoformed 334 
vessels and normal, preexistent vessels in neoplastic and nonneoplastic tissues 335 
(Gee et al., 2003). So, to avoid mistakes, we choose to asses only CD31 positive 336 
stain of structures with characteristics of neoformed vessels, which correlates with 337 
a more proliferation status of endothelial cells. Both large vessels with hyalinized 338 
walls and inflammatory cells with CD 31 positive stain were not counted. The last 339 
cells can be distinguished from endothelial cells on the basis of morphological 340 
differences. The quantification was performed by counting the number of cells or 341 
structures with characteristics of neoformed vessels which stained positively for 342 
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CD31 in 10 consecutive fields at x200 magnification. We detected that tumors 343 
resulting from subcutaneously implanted HCT 116 cells treated with PTHrP 344 
showed increased the number of cells or structures with characteristics of 345 
neoformed vessels (CD31+, neoformed structures) (Figure 1C). Taken together, 346 
these results suggest the pro-angiogenic effects of PTHrP in xenografts in vivo. 347 
 348 
3.2. PTHrP increases mRNA levels of the factors involved in angiogenesis, 349 
VEGF, HIF-1α and MMP-9, in Caco-2 and HCT 116 cell lines. 350 
In view of the results observed in vivo, the next goal was to study if the hormone 351 
also increases mRNA levels of VEGF in the colon cancer Caco-2 and HCT116 352 
cells. According to the results obtained in vivo, RT-qPCR assays revealed that 353 
mRNA levels of the angiogenic factor VEGF are increased after PTHrP treatment 354 
(10-8 M) for 20 h in both cell lines (Figure 2). Moreover, the hormone also 355 
increased the mRNA levels of others molecules involved in angiogenesis as HIF-356 
1α and MMP-9 (Figure 2). 357 
 358 
3.3. Colon cancer cells exposed to PTHrP increases the number of 359 
endothelial cells. 360 
Tumor angiogenesis is established and maintained by a complex molecular and 361 
cellular crosstalk between tumor cells and endothelial cells. Thus, we employed 362 
HMEC-1 cells, an immortalized cell line of human microvascular endothelial cells, 363 
and TCMs to evaluate the effect on endothelial cells of the factors released from 364 
colon cancer cells exposed to PTHrP and so to test tumor angiogenic potential of 365 
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the hormone in vitro. To that end, we first carried out studies to test whether TCMs 366 
from colon cancer cells treated with PTHrP modify the number of endothelial cells. 367 
The evaluation of endothelial cells number by staining with the basic crystal violet 368 
dye revealed that TCMs from colon cancer cells treated with PTHrP for 24 hours 369 
increased the absorbance by 23.2 % (TCMs from PTHrP-treated Caco-2 cells) and 370 
27.4 % (TCMs from PTHrP-treated HCT 116 cells) with respect to cells exposed to 371 
control TCMs (Figure 3A). Also, counting live cells (which are not stained with 372 
trypan blue in a Neubauer chamber) revealed an increase of 53% and 62% in 373 
endothelial cell number after 24 hours of exposure to TCMs from Caco-2 or HCT 374 
116 cells treated with PTHrP, respectively (Figure 3B). Finally, endothelial cells 375 
treated with TCMs were incubated with resazurin and, upon treatment; the 376 
metabolic capacity of these cells was measured. We found that TCMs from colon 377 
cancer cells treated with PTHrP increase the bioreduction of resazurin, which was 378 
accompanied by a corresponding increment in fluorescent measurement by 49.8 % 379 
(TCMs from PTHrP-treated Caco-2 cells) and 57.3 % (TCMs from PTHrP-treated 380 
HCT 116 cells) with respect to cells exposed to control TCMs (Figure 3C). Taking 381 
together, these results indicate that TCMs from colon cancer cells treated with 382 
PTHrP increases the number of endothelial cells. Based on these findings, then we 383 
studied whether the increased number of HMEC-1 cells occurs from an increased 384 
rate of proliferation or a decreased rate of cell death or both. So we evaluated the 385 
expression of relevant molecular markers associated with apoptosis and 386 
proliferation regulation by Western blot analysis. We observed that TCMs from 387 
CRC cells treated with the hormone increase the protein levels of PCNA 388 
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(proliferating cell nuclear antigen), which is a well-known cell proliferation indicator; 389 
however, the expression levels of poly-ADP ribose polymerase (PARP), which is 390 
an apoptotic marker, did not change (data not shown). Although these results 391 
suggest a proliferative effect, more research is required to confirm this hormonal 392 
action. 393 
 394 
3.4. Colon cancer cells exposed to PTHrP enhance the migration of 395 
endothelial cells. 396 
As during tumor angiogenesis the endothelial cells migrate to generate tumor 397 
vasculature, then we evaluated the migratory properties of HMEC-1 cells using 398 
transwell inserts and TCMs, as is described in materials and methods. Under these 399 
conditions, the endothelial cells were allowed to migrate for 16 h. As shown in 400 
Figure 4A, TCMs collected from colon cancer cells treated with the hormone for 24 401 
h markedly increase the endothelial cells mobility. Similar data were obtained when 402 
the endothelial cells were co-cultured employing transwell inserts with colon cancer 403 
cells which were pre-treated with PTHrP (Figure 4B). The HMEC-1 cell migration 404 
in the control groups (TCMs or cells without PTHrP treatment, Figure 4A and B, 405 
respectively) is probably due to endogenous expression of proangiogenic 406 
molecules by the colon cancer cells independently of PTHrP treatment. 407 
 408 
3.5. Colon cancer cells exposed to PTHrP induce the formation of tube-like 409 
structures in endothelial cells.  410 
 411 
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To additionally investigate the PTHrP role in the tumor-associated angiogenesis 412 
process, we employed the tube formation assay using geltrex matrix to evaluate 413 
the capacity of endothelial cells to form an organized tubular network. HMEC-1 414 
cells were seeded on geltrex and they were incubated with the corresponding 415 
TCMs. After 24 hours cells were photographed under an inverted light microscope. 416 
As shown in Figure 5A, TCMs from colon cells treated with PTHrP induced the 417 
formation of tube-like structures in endothelial cells seeded on geltrex and also 418 
formed a net structure composed of connected HMEC-1 cells. The quantification of 419 
the structures from three independent experiments by the Image J program, 420 
demonstrated a remarkable increase in the number of nodes, junctions, branching 421 
points and in the total branching length (Figure 5B). 422 
 423 
3.6. PTHrP promotes tumor angiogenesis mainly through VEGF  424 
As the number, migration and formation of tube-like structures of HMEC-1 cells 425 
were increased in response to a hormone indirect effect (Caco-2 or HCT 116-426 
dependent), we presumed that the hormone promotes tumor angiogenesis mainly 427 
through the secretion of proangiogenic factors from stimulated colon cancer cells. 428 
Normally, VEGF would be secreted by cancer cells into the surrounding 429 
environment, acting on endothelial cells to drive their proliferation, survival, 430 
chemotaxis and migration, and leading to tumor angiogenesis (Greenberg et al., 431 
2008). As PTHrP increases mRNA levels of this angiogenic factor in colon cancer 432 
cells, so we sought to investigate if the hormone has an indirect action on 433 
endothelial cells through VEGF performing studies with a neutralizing antibody 434 
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against VEGF. We evaluated if the response of HMEC-1 cells observed previously 435 
by us is the same or is different when these cells were exposed to TCMs which 436 
were pre-incubated for 2 h at 37 °C with the anti-VEGF antibody or with an 437 
appropriate isotype-matched control rabbit IgG. As shown in Figures 6A, B and C, 438 
anti-VEGF antibody attenuated the stimulatory effects of TCMs on endothelial cells 439 
in vitro. Collectively, these findings indicate that PTHrP increases the expression of 440 
the angiogenic VEGF in Caco-2 and HCT 116 cells, which in turn is secreted to the 441 
culture medium and thus the hormone exerts its effects on endothelial cells in a 442 
colon cancer cells dependent manner. 443 
 444 
3.7. PTHrP increases mRNA levels of VEGF, HIF-1α and MMP-9 in Caco-2 and 445 
HCT 116 cell lines via ERK1/2 and PI3K/AKT signaling pathways. 446 
 447 
In previous studies, we obtained evidence that the hormone increases the 448 
proliferation, migration, survival and chemoresistance via MAPKs and PI3K/AKT 449 
signaling pathways in the colon cancer Caco-2 cells and HCT116 cells (Lezcano et 450 
al., 2013; Martín et al., 2014; Calvo et al., 2014; Calvo et al., 2017; Martín et al., 451 
2018). ERK1/2 and AKT are central proteins in many cellular pathways leading to 452 
angiogenesis (Xu et al., 2015; Dong et al., 2017). So, to investigate the relation 453 
between ERK 1/2 MAPK and PI3K/AKT signaling pathways triggered by PTHrP 454 
and the tumor associated-angiogenesis process, colon cancer cells were 455 
pretreated with PD 98059 (20 µM) (an inhibitor of the upstream kinase of ERK1/2, 456 
MEK), LY294002 (50 µM) (an inhibitor of PI3K) or GSK 690693 (0.1 µM) (an 457 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
inhibitor of AKT kinase) and then treated with PTHrP followed by RT-qPCR 458 
analysis. As shown in Figure 7A, ERK1/2 and PI3K/AKT inhibitors reversed the 459 
increase of mRNA levels of VEGF, HIF-1α and MMP-9 in Caco-2 and HCT 116 cell 460 
lines exposed to PTHrP. Taken together, these results suggest that the effect of 461 
PTHrP on the expression of these proangiogenic factors is dependent on ERK 1/2 462 
and PI3K/AKT pathways.  463 
Then, to determine if ERK1/2 and AKT mediate the angiogenic potential of colon 464 
cancer cells induced by PTHrP, we employed TCMs from colon cancer cells 465 
pretreated for 30 min with PD 98059, LY 294002 or GSK 690693, to inhibit ERK 466 
1/2 and AKT activity, following with the incubation with PTHrP for 24 hours as 467 
described in materials and methods. The inhibition of ERK1/2 and PI3K/AKT 468 
signaling pathways in colon cancer cells abrogated the stimulatory effects of Caco-469 
2 and HCT 116 cells on HMEC-1 migration (Figure 7B). Taken together, these 470 
results suggest that the activation of Akt and ERK1/2 by PTHrP in both cell lines is 471 
an early and upstream event leading to the induction of VEGF expression and 472 
subsequent angiogenic behavior of HMEC-1 cells mediated by secreted VEGF.   473 
 474 
3.8. PTHrP by direct treatment increases the phosphorylation of ERK1/2 and 475 
the cells number but not stimulates migration neither tube formation of 476 
endothelial cells 477 
Results showed that TCMs from colon cancer cells exposed to PTHrP induce an 478 
increase in the number of cells, migration and the formation of tube-like structures 479 
in HMEC-1 cells. In order to verify if PTHrP also exerts direct effects (colon cancer 480 
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cells-independent) on endothelial cell angiogenic behavior, HMEC-1 cells were 481 
exposed directly to PTHrP and the cell number, migration and tube formation of 482 
these cells were assessed. First, lysates from HMEC-1 cells was tested for the 483 
presence of PTH/PTHrP receptor, PTHR1. Western blot analysis showed the 484 
presence of a PTH binding component of 90 KDa which is the size for the mature 485 
PTHR1 (Kaufmann et al., 1994) (Figure 8A). Then, we investigate if the hormone 486 
is able to activate MAP kinase signaling in endothelial cells, studying the 487 
phosphorylation of ERK1/2. So, HMEC-1 cells were exposed with PTHrP (10-8 M) 488 
for different times and then western blot analyses were performed with an antibody 489 
that recognizes the active form of the ERK1/2. As shown in Figure 8B, PTHrP 490 
increased the phosphorylation on tyrosine residue of ERK1/2 at 1 hour of treatment 491 
but no effects were observed for longer periods. Then, we added the hormone 492 
directly to the endothelial cells and then we evaluated the number of HMEC-1 cells 493 
by three different methods: crystal violet staining, Trypan blue dye exclusion assay 494 
and resazurin reagent. Also, we evaluated their migratory properties using 495 
transwell inserts and the formation of tube-like structures employing tube formation 496 
assay using geltrex matrix. By staining the cell with the basic crystal violet dye we 497 
observed that the treatment with the hormone for 24 hours at a dose of 10-7 and 498 
10-8 M increased the absorbance by 27% and 42% respectively with respect to 499 
untreated cells (Figure 8C). Counting live cells that are not stained with trypan blue 500 
in a Neubauer chamber revealed that PTHrP at a dose of 10-7 and 10-8 M for 24 501 
hours of treatment also increase endothelial cell number by 44% and 60% 502 
respectively with respect to untreated cells (Figure 8C). Furthermore, we found 503 
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that PTHrP at a dose of 10-8 M for 24 hours of treatment increase the bioreduction 504 
of resazurin, which was accompanied by a corresponding increment in fluorescent 505 
measurement by 27 % with respect to cells exposed to control (Figure 8C). This 506 
endothelial cells response to PTHrP was completely reversed in the presence of 507 
the ERK1/2 inhibitor (data not shown). Taken together, these results indicate that 508 
PTHrP by direct action increases the number of endothelial cells. PTHrP added 509 
directly to the cells increased the protein levels of PCNA but did not promote 510 
PARP-degradation (data not shown); these findings suggest that the hormone has 511 
a proliferative effect but more research is required to confirm this hormonal action. 512 
Despite this PTHrP effect on cell accumulation, we found that the hormone (10-8 M) 513 
directly added to the cells or as chemoattractant did not modify migration of HMEC-514 
1 cells (Figure 8D). Moreover, direct treatment with PTHrP (10-7 - 10-8 M) for 24 515 
hours did not stimulate the tube formation of endothelial cells (Figure 8E). Neither 516 
was observed when HMEC-1 cells were exposed with the hormone for 48 hours 517 
(data not shown). Overall, these results suggest that PTHrP exerts its effects on 518 
endothelial cell angiogenic behavior through a colon cancer cells-dependent 519 
manner. 520 
 521 
4. Discussion 522 
CRC is one of the main causes of death for cancer in the world (Siegelet al., 2017). 523 
At the time of diagnosis several patients have metastatic CRC (mCRC) and 524 
approximately half of those who have undergone surgery for CRC at an early stage 525 
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will develop mCRC (Young et al., 2014). Despite improvements in treatments for 526 
mCRC, there are still deficiencies and it is necessary more efficient and tolerable 527 
alternatives in mCRC therapy. 528 
Recently we obtained evidence that PTHrP in HCT 116 xenografts of nude mice 529 
increased the expression of markers related to tumorigenic events and it positively 530 
modulates RSK, ERK1/2, p38 MAPK and PI3K/AKT signaling pathways in cell lines 531 
from human colorectal adenocarcinoma. The hormone also increases cell 532 
proliferation, promotes cell cycle progression, enhances cell migration, induces 533 
chemoresistance and has a protective effect in conditions of apoptosis by the 534 
regulation of these signaling pathways (Lezcano et al., 2013; Martín et al., 2014; 535 
Calvo et al., 2014; Calvo et al., 2017; Martín et al., 2018). We think that other 536 
possible PTHrP action mode on cells derived from CRC is through the release of 537 
bioactive factors induced by the hormone which facilitate tumor growth. The 538 
successful tumor growth and establishment of metastasis relies on angiogenesis 539 
(Ronca et al., 2017). Several studies have been carried out to elucidate the 540 
process of angiogenesis, studying its role in the growth of the primary tumor and 541 
the metastasis; they provided promising results and allowed the development of 542 
proangiogenic inhibitors such as bevacizumab (a humanized antibody against 543 
VEGF) used in combination with chemotherapy for the treatment of tumors such as 544 
mCRC (Sánchez-Gundín et al., 2018). However, due to the generation of 545 
resistance, it is important to review and continue with the investigation of this 546 
process and its regulation to outline new alternative therapies for cancer.  547 
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Within the vasculature, endothelial cells produce PTHrP, while there are different 548 
reports regarding the expression of the PTH/PTHrP receptor. Rian and 549 
collaborators (Rian et al., 1994) showed for the first time that PTHrP, but not the 550 
PTH/PTHrP receptor, is produced by human endothelial cells. As smooth muscle 551 
cells express PTH/PTHrP receptors (Funk et al., 2002), these investigators 552 
suggest that the hormone produced by endothelial cells may has a paracrine action 553 
on these muscle cells (Diamond et al., 2006), however, they cannot rule out an 554 
autocrine effect of PTHrP.  555 
Curiously, there are controversial results about the effects of PTHrP on 556 
angiogenesis. Despite several works suggested that the peptide has a role in this 557 
process, the data are contradictory (Akino et al., 2000; Bakre et al., 2002). So, 558 
further research is needed to establish if PTHrP may stimulate or not tumor 559 
angiogenesis.  560 
An inhibitory role of PTHrP on angiogenesis was first found by Bakre and 561 
collaborators (Bakre et al., 2002). They observed that the hormone inhibits tumor-562 
associated angiogenesis in prostate tumors (Bakre et al., 2002). Consistent with 563 
the inhibitory effect, the impact of the expression pattern of PTHrP on hair growth 564 
also suggest an inhibitory role in the angiogenesis (Diamond et al., 2006; Skrok et 565 
al., 2015). Furthermore, Deckers and collaborators showed that the treatment with 566 
the hormone significantly decreased VEGF levels in a model of osteoblast 567 
differentiation (Deckers et al., 2000). 568 
In the other hand, other authors demonstrated that PTHrP rapidly and transiently 569 
stimulates the expression of VEGF in osteoblasts (Esbrit et al., 2000; de Gortazar 570 
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et al., 2006; Alonso et al., 2011), suggesting a role of the hormone as an 571 
angiogenesis stimulator. Esbrit and collaborators also observed that CMs from 572 
osteoblastic cells treated with the hormone increase the growth of bovine aortic 573 
endothelial cells (BAEC) (Esbrit et al., 2000). Subsequent reports indicated that 574 
PTHrP stimulated bone angiogenesis mainly by its effects on osteoclasts 575 
(Cackowski et al., 2010; Zhu et al., 2013). A stimulatory effect of PTHrP on 576 
angiogenesis was also reported by Akino and collaborators (Akino et al., 2000). 577 
They observed that rat pituitary malignant tumor cells, mGH3, that overexpress 578 
PTHrP compared to original GH3 cells, show hypervascularization in xenografts in 579 
vivo. Moreover, they reported that PTHrP increased capillary formation by BAECs 580 
endothelial cells (Akino et al., 2000). Another reported role of PTHrP in the 581 
regulation of angiogenesis is important in the prostate cancer (Park and McCauley, 582 
2012). The hormone can induce the expression of IL8, an angiogenic factor, in 583 
PCa prostate cancer cells by an intracrine manner independent of its classical 584 
nuclear localization sequence (Gujral et al., 2001). In addition, prostate cancer-585 
derived PTHrP has a pro-angiogenic role indirectly, by stimulating of different 586 
angiogenic factors in bone marrow stromal cells (BMSCs) (Liao et al., 2008) and 587 
increasing the recruitment and angiogenic potential of the bone marrow-derived 588 
cells, CD11b+Gr1+ cells (Park et al., 2013). There is also a link between PTHrP and 589 
VEGF in breast cancer bone metastasis. The hormone modulates breast tumor cell 590 
angiogenesis by the regulation of expression levels of critical factors such as 591 
VEGF (Isowa et al., 2010), factor VIII (Li et al., 2011), and the connective tissue 592 
growth factor (CTGF/CCN2) (Shimo et al., 2006). 593 
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Contradictory data may due to the diverse interactions in the microenvironment 594 
where there are different target cells of PTHrP. The differences in the expression of 595 
the PTHR1 receptor in endothelial cells may also contribute. Although, it is unclear 596 
if PTHrP can directly inhibit or stimulate endothelial cells, in most reports, the 597 
hormone has a role in tumor angiogenesis as a key mediator for communication 598 
and interactions between cancer cells and the microenvironment by stimulating the 599 
production of a number of angiogenic factors. Moreover, different fragments of 600 
PTHrP may have differing effects on endothelial cells. 601 
In this study, we investigated, for the first time, the roles of PTHrP(1-34) on tumor 602 
angiogenesis using colon cancer and endothelial cells and a mouse model. We 603 
observed that PTHrP treatment increases both mRNA and protein levels of the pro-604 
angiogenic factor VEGF and the number of structures with characteristics of 605 
neoformed vessels in HCT 116 xenografts tumor. Other authors showed a 606 
correlation between PTHrP and key markers of angiogenesis process in human 607 
tumors such as human prostate cancer and clear cell renal cell carcinoma (Liao et 608 
al., 2008; Feng et al., 2013). These previous results provide support for the 609 
potential clinical relevance of our observations. Studies with biopsies of CRC 610 
patients are necessary to perform to evaluate the significance of our work. 611 
The hormone also increases the mRNA levels of VEGF and others factors involved 612 
in angiogenesis, HIF-1α and MMP-9, in Caco-2 and HCT 116 cell lines. The use of 613 
specific inhibitors of ERK1/2, PI3K, and Akt suggest that these signaling pathways 614 
participate in this response to PTHrP (1-34). Despite pharmacological inhibitors 615 
can be useful tools to explore the involvement of signaling pathways in cellular 616 
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responses to a given hormone, the limitations and off-target effects of employed 617 
inhibitors need to be carefully considered in the interpretation of experimental data. 618 
Therefore, further researches are required to support the involvement of these 619 
signaling pathways in this cellular response to PTHrP. 620 
TCM from cultured media of Caco-2 and HCT 116 cells treated with the hormone 621 
markedly increased the number and the migration of HMEC-1 endothelial cells. 622 
Similar data were obtained using co-culture assays. In addition, TCM from colon 623 
cancer cells exposed to PTHrP induced the formation of tube-like structures in 624 
endothelial cells. Studies with a neutralizing antibody against VEGF diminished the 625 
response of endothelial cells exposed to TCMs suggesting that this response is 626 
associated with enhanced production of VEGF. 627 
Herein we employed two CRC cell lines with phenotypic differences (Caco-2 cells 628 
and HCT116 cells) with the aim to evaluate whether their response to PTHrP are 629 
similar or different in these two types of tumor intestinal cells. It is known that 630 
mutations in KRAS and PIK3CA genes are reflected in the HCT116 cell line (KRAS 631 
and PIK3CA mutant) but not in Caco-2 cell line (KRAS and PIK3CA WT) 632 
(Botchkina et al., 2009). In other hand, it has been reported that the mutations of 633 
APC gene is very frequent in several CRC cell lines as Caco-2 (APC mutant), 634 
however, this mutation is not present in HCT116 cell line (APC WT) (Ilyas et al., 635 
1997). Although mutations of KRAS, PIK3CA and APC correlate with VEGF 636 
expression and angiogenesis (Yeh et al., 2017; Chen et al., 2018; Lai et al., 2015; 637 
Zhang et al., 2003; Baudino et al., 2002; Yekkala and Baudino, 2007), the fact that 638 
both cell lines have similar response to PTHrP support the idea about that the 639 
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induction of tumor angiogenesis by PTHrP is independent of these mutation 640 
statuses. 641 
In conclusion, the studies carried out in this work show, for the first time, that 642 
PTHrP signaling stimulates the production of VEGF in colon cancer cells which 643 
acts in the tumor microenvironment promoting the angiogenesis. These results 644 
agree with the hypothesis that PTHrP mediates the communication between colon 645 
cancer cells and the endothelial cells by stimulating the production of angiogenic 646 
factors.  647 
In the other hand, PTHrP by direct treatment only increased the phosphorylation of 648 
ERK1/2 and the cells number but not stimulated the migration neither tube 649 
formation of HMEC-1 cells and these findings rule out a proangiogenic effect of the 650 
hormone by its direct action on these endothelial cells and also indicate that PTHrP 651 
alone is not enough to regulate tumor angiogenesis. 652 
Taken together, these results provide new insights of colon tumor cell behavior 653 
induced by PTHrP (1-34); also, this work provides the first evidence related to the 654 
paracrine/autocrine mode of action of PTHrP (1-34) that leads to its proangiogenic 655 
effects in the CRC which is indirect and involves the interaction of colon tumor cells 656 
with the microenvironment endothelial cells.  657 
The elucidation of the indirect regulation of the hormone on this process is very 658 
important and of great interest for the understanding of the different roles of PTHrP 659 
in the colon cancer and its relationship with the angiogenesis. Further researches 660 
are required to evaluate the possible role of the other PTHrP fragments in the 661 
CRC, and if the hormone also acts in an intracrine manner. 662 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
30 
 
 663 
Declaration of interest  664 
There is no conflict of interest that could be perceived as prejudicing the 665 
impartiality of the research reported. 666 
 667 
Funding and acknowledgements 668 
 669 
This work was supported by grants from the Agencia Nacional de Promoción 670 
Científica y Tecnológica (ANPCYT) (PICT-2013-1441), Consejo Nacional de 671 
Investigaciones Científicas y Técnicas (CONICET) (PIP11220150100350), Instituto 672 
Nacional del Cáncer (Asistencia Financiera III-2016-2017, RESOL-2016-1006-E-673 
APN-MS) and Universidad Nacional del Sur (PGI: 24/B188; PGI: 24/B230), 674 
Argentina.  675 
 676 
References 677 
 678 
Akino K, Ohtsuru A, Kanda K et al. Parathyroid hormone-related peptide is a potent 679 
tumor angiogenic factor. Endocrinology. 2000;141:4313–4316. 680 
 681 
Alonso V, de Gortázar AR, Ardura JA et al. Parathyroid hormone-related protein 682 
(107-139) increases human osteoblastic cell survival by activation of vascular 683 
endothelial growth factor receptor-2. J Cell Physiol. 2008;217:717-727. 684 
 685 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
31 
 
Avdalyan A, Bobrov I, Klimachev V et al. Prognostic Value of Microvessel Density 686 
in Tumor and Peritumoral Area as Evaluated by CD31 Protein Expression and 687 
Argyrophilic Nucleolar Organizer Region Count in Endothelial Cells in Uterine 688 
Leiomyosarcoma. Sarcoma. 2012;2012:594512.  689 
 690 
Bakre MM, Zhu Y, Yin H et al. Parathyroid hormone-related peptide is a naturally 691 
occurring, protein kinase A-dependent angiogenesis inhibitor. Nat Med. 692 
2002;8:995–1003. 693 
 694 
Battaglin F, Puccini A, Intini R et al. The role of tumor angiogenesis as a 695 
therapeutic target in colorectal cancer.  Expert Rev Anticancer Ther. 2018;19:1-16. 696 
 697 
Baudino TA, McKay C, Pendeville-Samain H, et al. c-Myc is essential for 698 
vasculogenesis and angiogenesis during development and tumor progression. 699 
Genes Dev. 2002;16(19):2530-43. 700 
 701 
Bhattacharya R, Ye XC, Wang R et al. Intracrine VEGF Signaling Mediates the 702 
Activity of Prosurvival Pathways in Human Colorectal Cancer Cells. Cancer Res. 703 
2016;76:3014-3024.  704 
 705 
Botchkina IL, Rowehl RA, Rivadeneira DE et al. Phenotypic subpopulations of 706 
metastatic colon cancer stem cells: genomic analysis. Cancer Genomics 707 
Proteomics. 2009;6(1):19-29. 708 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
32 
 
 709 
Bradford M. A rapid and sensitive method for quantification of microgram quantities 710 
of proteins utilizing the principle of protein binding. Anal Biochem. 1976; 72:248–711 
254. 712 
 713 
Cackowski FC, Anderson JL, Patrene KD et al. Osteoclasts are important for bone 714 
angiogenesis. Blood. 2010;115:140-149.  715 
 716 
Calvo N, Carriere P, Martin MJ et al. RSK activation via ERK modulates human 717 
colon cancer cells response to PTHrP. J Mol Endocrinol. 2017;59:13-27.  718 
 719 
Calvo N, Martín MJ, de Boland AR et al. Involvement of ERK1/2, p38 MAPK, and 720 
PI3K/Akt signaling pathways in the regulation of cell cycle progression by PTHrP in 721 
colon adenocarcinoma cells. Biochem Cell Biol. 2014;92:305-315. 722 
 723 
Carpentier G. Angiogenesis analyzer, Image. J. News. 2012. Available from: 724 
http://image.bio.methods.free.fr/ImageJ/?Angiogenesis-Analyzer-for-ImageJ 725 
 726 
Chen M, Lin M, Wang X. Overexpression of miR-19a inhibits colorectal cancer 727 
angiogenesis by suppressing KRAS expression. Oncol Rep. 2018;39(2):619-626.  728 
 729 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
33 
 
Chim SM, Qin A, Tickner J et al. EGFL6 promotes endothelial cell migration and 730 
angiogenesis through the activation of extracellular signal-regulated kinase. J Biol 731 
Chem. 2011;286:22035-22046.  732 
 733 
de Gortazar AR, Alonso V, Alvarez-Arroyo MV et al. Transient exposure to PTHrP 734 
(107-139) exerts anabolic effects through vascular endothelial growth factor 735 
receptor 2 in human osteoblastic cells in vitro. Calcif Tissue Int. 2006;79:360-369. 736 
 737 
Deckers MM, Karperien M, van der Bent C et al. Expression of vascular endothelial 738 
growth factors and their receptors during osteoblast differentiation. Endocrinology. 739 
2000;141:1667-74. 740 
 741 
Diamond AG, Gonterman RM, Anderson AL et al. Parathyroid hormone hormone 742 
related protein and the PTH receptor regulate angiogenesis of the skin. J Invest 743 
Dermatol. 2006;126:2127–2134. 744 
 745 
Domigan CK, Ziyad S, Iruela-Arispe ML. Canonical and noncanonical vascular 746 
endothelial growth factor pathways: new developments in biology and signal 747 
transduction. Arterioscler Thromb Vasc Biol. 2015;35:30-39.  748 
 749 
Dong Y, Wu G, Zhu T et al. VEGF promotes cartilage angiogenesis by phospho-750 
ERK1/2 activation of Dll4 signaling in temporomandibular joint osteoarthritis 751 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
34 
 
caused by chronic sleep disturbance in Wistar rats. Oncotarget. 2017;8:17849-752 
17861.  753 
 754 
Esbrit P, Alvarez-Arroyo MV, De Miguel F et al. C-Terminal parathyroid hormone-755 
related protein increases vascular endothelial growth factor in human osteoblastic 756 
cells. J Am Soc Nephrol. 2000;11:1085-1092. 757 
 758 
Feng CC, Ding GX, Song NH, et al. Paraneoplastic hormones: parathyroid 759 
hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular 760 
endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma 761 
Tumour Biol. 2013;34:3471-6 762 
 763 
Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1–18. 764 
 765 
Funk JL, Wei H, Downey KJ et al. Expression of PTHrP and its cognate receptor in 766 
the rheumatoid synovial microcirculation. Biochem Biophys Res Commun. 767 
2002;297:890–897. 768 
 769 
Gee MS, Procopio WN, Makonnen S et al. Tumor vessel development and 770 
maturation impose limits on the effectiveness of anti-vascular therapy. Am J 771 
Pathol. 2003;162:183-93. 772 
 773 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
35 
 
Greenberg JI, Shields DJ, Barillas SG et al. A role for VEGF as a negative 774 
regulator of pericyte function and vessel maturation. Nature. 2008;456:809–813. 775 
 776 
Gujral A, Burton DW, Terkeltaub R et al. Parathyroid hormone‐related protein 777 
induces interleukin‐8 production by prostate cancer cells via a novel intracrine 778 
mechanism not mediated by its classical nuclear localization sequence. Cancer 779 
Res. 2001;61:2282-2288. 780 
 781 
Hammoud L, Adams JR, Loch AJ et al. Identification of RSK and TTK as 782 
Modulators of Blood Vessel Morphogenesis Using an Embryonic Stem Cell-Based 783 
Vascular Differentiation Assay. Stem Cell Reports. 2016;7:787-801.  784 
 785 
Hong N, Yoon HJ, Lee YH et al. Serum PTHrP Predicts Weight Loss in Cancer 786 
Patients Independent of Hypercalcemia, Inflammation, and Tumor Burden. J Clin 787 
Endocrinol Metab. 2016;101:1207-1214.  788 
 789 
Ilyas M, Tomlinson IP, Rowan A, et al. Beta-catenin mutations in cell lines 790 
established from human colorectal cancers. Proc Natl Acad Sci U S A. 791 
1997;94(19):10330-4. 792 
 793 
Isowa S, Shimo T, Ibaragi S et al. PTHrP regulates angiogenesis and bone 794 
resorption via VEGF expression. Anticancer Res. 2010;30:2755-2767. 795 
 796 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
36 
 
Kaufmann M, Muff R, Born W et al. Functional expression of a stably transfected 797 
parathyroid hormone/parathyroid hormone related protein receptor complementary 798 
DNA in CHO cells. Mol Cell Endocrinol. 1994;104:21-27. 799 
 800 
Koch S, Tugues S, Li X et al. Signal transduction by vascular endothelial growth 801 
factor receptors. Biochem J. 2011;437:169–183. 802 
 803 
Kong DH, Kim MR, Jang JH et al. A Review of Anti-Angiogenic Targets for 804 
Monoclonal Antibody Cancer Therapy. Int J Mol Sci. 2017;18: pii: E1786.  805 
 806 
Lai K, Killingsworth MC, Lee CS. Gene of the month: PIK3CA. J Clin Pathol. 807 
2015;68(4):253-7.  808 
 809 
Lezcano V, Gentili C, de Boland AR. Role of PTHrP in human intestinal Caco-2 cell 810 
response to oxidative stress. Biochim Biophys Acta.  2013;1833:2834-2843.  811 
 812 
Li J, Karaplis AC, Huang DC et al. PTHrP drives breast tumor initiation, 813 
progression, and metastasis in mice and is a potential therapy target. J Clin Invest. 814 
2011;121:4655-4669.  815 
 816 
Liao J, Li X, Koh AJ et al. Tumor expressed PTHrP facilitates prostate cancer-817 
induced osteoblastic lesions. Int J Cancer. 2008;123:2267–2278. 818 
 819 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
37 
 
Loizzi V, Del Vecchio V, Gargano G et al. Biological Pathways Involved in Tumor 820 
Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special 821 
References to Ovarian Cancer. Int J Mol Sci. 2017;18:pii: E1967.  822 
 823 
Mahfouz N, Tahtouh R, Alaaeddine N et al. Gastrointestinal cancer cells treatment 824 
with bevacizumab activates a VEGF autoregulatory mechanism involving 825 
telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1α and VEGF receptors. 826 
PLoS One. 2017;12:e0179202.  827 
 828 
Martín MJ, Calvo N, de Boland AR et al. Molecular mechanisms associated with 829 
PTHrP-induced proliferation of colon cancer cells. J Cell Biochem. 2014;115:2133-830 
2145. 831 
 832 
Martín MJ, Gigola G, Zwenger A et al. Potential therapeutic targets for growth 833 
arrest of colorectal cancer cells exposed to PTHrP. Mol Cell Endocrinol. 834 
2018;478:32-44. 835 
 836 
McCauley LK, Martin TJ. Twenty-five years of PTHrP progress: from cancer 837 
hormone to multifunctional cytokine. J Bone Miner Res. 2012;27:1231-1239.  838 
 839 
Nikitovic D, Kavasi RM, Berdiaki A et al. Parathyroid hormone/parathyroid 840 
hormone-related peptide regulates osteosarcoma cell functions: Focus on the 841 
extracellular matrix (Review). Oncol Rep. 2016;36:1787-1792.  842 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
38 
 
 843 
Park SI, Lee C, Sadler WD et al. Parathyroid hormone-related protein drives a 844 
CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer 845 
growth. Cancer Res. 2013;73:6574-6583. 846 
 847 
Park SI, McCauley LK. Nuclear localization of parathyroid hormone-related peptide 848 
confers resistance to anoikis in prostate cancer cells. Endocr elat Cancer. 849 
2012;19:243-254.  850 
 851 
Rian E, Jemtland R, Olstad OK et al. Parathyroid hormone-related protein is 852 
produced by cultured endothelial cells: a possible role in angiogenesis. Biochem 853 
Biophys Res Commun.1994;198:740–747. 854 
 855 
Ronca R, Benkheil M, Mitola S et al. Tumor angiogenesis revisited: Regulators and 856 
clinical implications. Med Res Rev. 2017;37:1231-1274.  857 
 858 
Sánchez-Gundín J, Fernández-Carballido AM, Martínez-Valdivieso L et al. New 859 
Trends in the Therapeutic Approach to Metastatic Colorectal Cancer. Int J Med Sci. 860 
2018;15:659-665. 861 
 862 
Shimo T, Kubota S, Yoshioka N et al. Pathogenic role of connective tissue growth 863 
factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res. 864 
2006;21:1045–1059. 865 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
39 
 
 866 
Shtivelband MI, Juneja HS, Lee S et al. Aspirin and salicylate inhibit colon cancer 867 
medium- and VEGF-induced endothelial tube formation: correlation with 868 
suppression of cyclooxygenase-2 expression. J Thromb Haemost. 2003;1:2225-869 
2233. 870 
 871 
Siegel RL, Miller KD, Fedewa SA et al. Colorectal cancer statistics, CA. Cancer J 872 
Clin. 2017;67:177-193.  873 
 874 
Skrok A, Bednarczuk T, Skwarek A et al. The effect of parathyroid hormones on 875 
hair follicle physiology: implications for treatment of chemotherapy-induced 876 
alopecia. Skin Pharmacol Physiol. 2015;28:213-225. 877 
 878 
Snedecor G, Cochran W. Statistical. Methods, 8th edition. Ames, IA, USA: Iowa. 879 
State. University. Press.1989. 880 
 881 
Wang Q, Li N, Wang X et al. Augmentation of sodium butyrate-induced apoptosis 882 
by phosphatidylinositol 3′-kinaseinhibition in the KM20 human colon cancer cell 883 
line. Clin Cancer Res. 2002,8:1940–1947. 884 
 885 
Wysolmerski JJ. Parathyroid hormone-related protein: an update. J Clin Endocrinol 886 
Metab. 2012;97:2947-2956.  887 
 888 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
40 
 
Xu J, Yi Y, Li L et al. Osteopontin induces vascular endothelial growth factor 889 
expression in articular cartilage through PI3K/AKT and ERK1/2 signaling. Mol Med 890 
Rep. 2015;12:4708-12.  891 
 892 
Yeh YW, Cheng CC, Yang ST, et al. Targeting the VEGF-C/VEGFR3 axis 893 
suppresses Slug-mediated cancer metastasis and stemness via inhibition of 894 
KRAS/YAP1 signaling. Oncotarget. 2017;8(3):5603-5618.  895 
 896 
Yekkala K, Baudino TA. Inhibition of intestinal polyposis with reduced angiogenesis 897 
in ApcMin/+ mice due to decreases in c-Myc expression. Mol Cancer Res. 898 
2007;5(12):1296-303.  899 
 900 
Young P, Womeldorph C, Johnson E et al. Early detection of colorectal cancer 901 
recurrence in patients undergoing surgery with curative intent: current status and 902 
challenges. J Cancer. 2014;5:262–271. 903 
 904 
Zhang L, Yang N, Katsaros D, et al. The oncogene phosphatidylinositol 3'-kinase 905 
catalytic subunit alpha promotes angiogenesis via vascular endothelial growth 906 
factor in ovarian carcinoma. Cancer Res. 2003;63(14):4225-31. 907 
 908 
Zheng X, Kang W, Liu H et al. Inhibition effects of total flavonoids from Sculellaria 909 
barbata D. Don on human breast carcinoma bone metastasis via downregulating 910 
PTHrP pathway. Int J Mol Med. 2018;41:3137-3146.  911 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
41 
 
 912 
Zhu K, Jiao H, Li S et al. ATF4 promotes bone angiogenesis by increasing VEGF 913 
expression and release in the bone environment. J Bone Miner Res. 914 
2013;28:1870-1884.  915 
 916 
Legends 917 
Figure 1. PTHrP increases mRNA levels and the expression of VEGF and the 918 
number of structures with characteristics of neoformed vessels in vivo. HCT 919 
116 xenograft tumors removed from nude mice were analyzed by: (A) RT-qPCR to 920 
evaluate the levels of mRNA VEGF in tumors treated with PTHrP respect to the 921 
levels observed in tumor treated with PBS. Bar graphs represent the mRNA levels 922 
of VEGF of three independent experiments; means ± s.d. are given. *P < 0.05 with 923 
respect to the corresponding control. We obtained the ∆CT according the following 924 
equation: ∆CT = CT of the gene of interest − CT GAPDH and mRNA levels 925 
according to the 2−∆CT equation and with respect to the corresponding control. (B) 926 
Immunohistochemistry. Tumor sections were stained with anti-VEGF antibody. 927 
Images (400X) are from tumor treated with PTHrP (right) and tumor untreated 928 
(left). Arrow indicates localization of VEGF near the nuclear membrane. (C) 929 
Immunohistochemistry. Tumor sections were stained with anti-CD31 antibody. 930 
Images (200X) are from tumor treated with PTHrP (right) and tumor untreated 931 
(left).  932 
 933 
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Figure 2. PTHrP increases mRNA levels of the factors involved in 934 
angiogenesis, VEGF, HIF-1α and MMP-9, in Caco-2 and HCT 116 cell lines. 935 
Colon cancer cells were treated with or without PTHrP 10-8 M for 3 and 20 h and 936 
the mRNA levels of these pro-angiogenic factors were analyzed by quantitative 937 
real-time RT-PCR (RT-qPCR) as described in Materials and methods. Bar graphs 938 
represent the mRNA levels of VEGF, HIF-1α and MMP-9 of three independent 939 
experiments; means ± s.d. are given. *P < 0.05 with respect to the corresponding 940 
control. 941 
 942 
Figure 3. Colon cancer cells exposed to PTHrP increases the number of 943 
endothelial cells.  (A) Crystal violet staining. A 96-well plate were seeded with 944 
HMEC-1 cells (20,000 cells/ well) and cultured with the corresponding TCMs at 37 945 
°C for 24 h. Then, the number of viable cells was determined by Crystal violet 946 
staining as described in materials and methods. Results were expressed as 947 
percentage relative to control of three independent measurements performed in 948 
triplicate. *P <0.05 with respect to the corresponding control. (B) Trypan blue dye 949 
exclusion. Cell counts were performed in a Neubauer chamber by means of 950 
trypan blue dye exclusion. The effects of each treatment have been compared with 951 
the control. The data shown are the average of cell number respect to control of 952 
three independent experiments. *P <0.05 with respect to the corresponding control. 953 
(C) Resazurin assay. The number of viable cells was determined by Resazurin 954 
staining. Results were expressed as percentage relative to control of three 955 
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independent measurements performed in triplicate. **P <0.01 with respect to the 956 
corresponding control. 957 
 958 
Figure 4. Colon cancer cells exposed to PTHrP enhance the migration of 959 
endothelial cells. We evaluated the migratory properties of HMEC-1 cells using 960 
transwell inserts and: (A) TCMs as chemoattractant. A total of 20,000 HMEC-1 961 
cells were seeded in medium without FBS in the upper chamber (on the top of 962 
transwell filters). Then, TCMs prepared as previously described in Materials and 963 
methods were added to the bottom chambers. After 16 h, HMEC-1 cells were fixed 964 
with methanol and stained with violet crystal. (B) Co-culture assays. Caco-2 and 965 
HCT 116 cells were plated into the lower chamber, grown for 48 h, serum starved 966 
for another 24 hours followed by the treatment with or without PTHrP. Then, a total 967 
of 20,000 HMEC-1 cells were seeded in medium without FBS in the upper 968 
chamber (on the top of transwell filters). After 16 h, HMEC-1 cells were fixed with 969 
methanol and stained with violet crystal. (C) The migrated cells were counted, and 970 
the quantification of the results expressed as percentage of migrated cells relative 971 
to control is shown. Data are representative of three independent experiments 972 
performed in triplicate. *P < 0.05.  973 
 974 
Figure 5. TCMs from colon cancer cells exposed to PTHrP induce the 975 
formation of tube-like structures in endothelial cells. A 96-well plate was 976 
coated with cold geltrex 50 µL/well and incubated at 37 °C to solidify the geltrex. 977 
HMEC-1 cells (20,000 cells/well)were seeded on geltrex-precoated wells and 978 
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cultured with the corresponding TCMs at 37 °C for 24 h. Cells were photographed 979 
under an inverted light microscope. (A) Representative photomicrographs of tube-980 
like formations by HMEC-1 cells are shown (100x). (B) Tube formation was 981 
quantified by using Angiogenesis Analyzer for ImageJ (NIH) by measuring the 982 
number of nodes, junctions and branching points and the total branching length. 983 
Data are representative of three independent experiments performed in triplicate. 984 
*P < 0.05.  985 
 986 
Figure 6. PTHrP promotes tumor angiogenesis mainly through VEGF. (A) 987 
Measuring of the cell number.  HMEC-1 cells were cultured at 37 °C for 24 h with 988 
the corresponding TCMs which were pre-incubated for 2 h at 37 °C with a specific 989 
neutralizing antibody directed against human VEGF or with an appropriate isotype-990 
matched control rabbit IgG. Then, the number of viable cells was determined by 991 
Crystal violet staining, Trypan blue dye exclusion and Resazurin assays as 992 
described in materials and methods. Results were expressed as percentage 993 
relative to control of three independent measurements performed in triplicate. *P 994 
<0.05, **P <0.01 with respect to the corresponding control. (B) Transwell 995 
migration assay. A total of 20,000 HMEC-1 cells were seeded in medium without 996 
FBS in the upper chamber (on the top of transwell filters). Samples of TCMs 997 
prepared as previously described in Materials and methods were pre-incubated for 998 
2 h at 37 °C with an specific neutralizing antibody directed against human VEGF 999 
(0.1 µg/ml). Appropriate isotype-matched control rabbit IgG were included. Then, 1000 
TCMs were added to the bottom chambers. After 16 h, cells were fixed with 1001 
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methanol and stained with violet crystal. The migrated cells were counted, and the 1002 
quantification of the results expressed as percentage of migrated cells relative to 1003 
control is shown. Data are representative of three independent experiments 1004 
performed in triplicate. *P < 0.05. (C) Tube formation assay.  A 96-well plate was 1005 
coated with cold geltrex50 µL/well and incubated at 37 °C to solidify the geltrex. 1006 
TCMs were pre-incubated for 2 h at 37 °C with an specific neutralizing antibody 1007 
directed against human VEGF or with an appropriate isotype-matched control 1008 
rabbit IgG. Then, HMEC-1 cells (20,000 cells/well) were seeded on geltrex-1009 
precoated wells and cultured with the corresponding TCMs at 37 °C for 24 h. Cells 1010 
were photographed under an inverted light microscope. Representative 1011 
photomicrographs of tube-like formations by HMEC-1 cells are shown (100x). 1012 
 1013 
Figure 7. PTHrP increases mRNA levels of VEGF, HIF-1α and MMP-9 in Caco-1014 
2 and HCT 116 cell lines via ERK1/2 and PI3K/AKT signaling pathways. (A) 1015 
Colon cancer cells were pre-incubated for 30 min with PD 98059 (20 µM), 1016 
LY294002 (50 µM) or GSK 690693 (50 µM) and then exposed to PTHrP 10−8 M for 1017 
20 h followed by RT-qPCR analysis as described in Materials and methods. Bar 1018 
graphs represent the mRNA levels of VEGF, HIF-1α and MMP-9 of three 1019 
independent experiments; means ± s.d. are given. *P < 0.05 with respect to the 1020 
corresponding control. (B) Transwell migration assay. A total of 20,000 HMEC-1 1021 
cells were seeded in medium without FBS in the upper chamber (on the top of 1022 
transwell filters). Then, TCMs prepared from colon cancer cell lines treated or not 1023 
with PTHrP either alone or combined with the corresponding inhibitors were added 1024 
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to the bottom chambers. After 16 h, cells were fixed with methanol and stained with 1025 
violet crystal. The migrated cells were counted, and representative photographs of 1026 
three independent experiments performed in triplicate are shown.  1027 
 1028 
Figure 8. Role direct of PTHrP in endothelial cells. (A) Western blot analysis of 1029 
HMEC-1 cell lysates was carried out using an anti-PTHR1 antibody. The 1030 
membranes were stripped and reblotted with anti-GAPDH antibody to ensure the 1031 
equivalence of protein loading. Caco-2 and HCT 116 cell lines were used as 1032 
positive control. A representative immunoblot is shown. (B) Time course of PTHrP- 1033 
induced phosphorylation of ERK 1/2 in endothelial cells. HMEC-1 cells were 1034 
treated with PTHrP (10−8 M) for different time intervals. Whole cell proteins were 1035 
extracted and Western blot was done using specific anti-MAPKs antibodies. The 1036 
membranes were stripped and re-blotted with anti-GAPDH antibody to ensure the 1037 
equivalence of protein content among the different experimental conditions. A 1038 
representative immunoblot and the quantification by scanning densitometry of 1039 
three independent experiments are shown; means±S.D. are given. *P<0.05 with 1040 
respect to the control. (C) Measuring of the cells number. HMEC-1 cells were 1041 
cultured with PTHrP (10-7 - 10-8 M) at 37 °C for 24 hours. Then, the number of 1042 
viable cells was determined by Crystal violet staining, Trypan blue dye exclusion 1043 
and Resazurin assays as described in materials and methods. Results were 1044 
expressed as percentage relative to control of three independent measurements 1045 
performed in triplicate. *P <0.05 with respect to the corresponding control. (D) 1046 
Transwell migration assay. We evaluated the migratory properties of HMEC-1 1047 
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cells using transwell inserts and PTHrP as chemoattractant or directly applied to 1048 
the cells in top panel and bottom panels, respectively. A total of 20,000 HMEC-1 1049 
cells were seeded in medium without FBS in the upper chamber (on the top of 1050 
transwell filters). Then, in some experiments, PTHrP was added to the bottom 1051 
chambers in PBS free medium as possible chemoattractant using FBS free 1052 
medium as a negative control. In others experiments the medium in filter inserts 1053 
was replaced by FBS free medium with or without PTHrP (10−8 M) and medium 1054 
containing 5% FBS was added in the lower chamber. After 16 h, HMEC-1 cells 1055 
were fixed with methanol and stained with violet crystal. The migrated cells were 1056 
counted, and representative photographs of three independent experiments 1057 
performed in triplicate are shown. (E) Tube formation assay using geltrex matrix 1058 
and the hormone directly applied to the cells to evaluate the formation of tube-like 1059 
structures. A 96-well plate was coated with cold geltrex 50 µL/well and incubated at 1060 
37 °C to solidify the geltrex. HMEC-1 cells (20,000 cells/well) were seeded on 1061 
geltrex-precoated wells and treated with PTHrP (10-7 - 10-8 M) in SFB-free medium 1062 
at 37 °C for 24 h. We used medium without FBS without PTHrP and TCM from 1063 
HCT116 cells treated with THrP as control negative and positive, respectively. 1064 
Cells were photographed under an inverted light microscope. Representative 1065 
photomicrographs of tube-like formations by HMEC-1 cells are shown (100x).  1066 
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Highlights:  
PTHrP has indirect proangiogenic effects in the CRC via VEGF. 
PTHrP mediates the interaction of colon tumor cells with the endothelial cells.  
PTHrP does not stimulate directly migration neither tube formation of endothelial 
cells. 
 
